ATE386535T1 - Hapten modifizierter tumorzellextrakt und verfahren zur behandlung von krebs - Google Patents

Hapten modifizierter tumorzellextrakt und verfahren zur behandlung von krebs

Info

Publication number
ATE386535T1
ATE386535T1 AT96921381T AT96921381T ATE386535T1 AT E386535 T1 ATE386535 T1 AT E386535T1 AT 96921381 T AT96921381 T AT 96921381T AT 96921381 T AT96921381 T AT 96921381T AT E386535 T1 ATE386535 T1 AT E386535T1
Authority
AT
Austria
Prior art keywords
tumor cell
modified tumor
disclosed
treating cancer
cell extract
Prior art date
Application number
AT96921381T
Other languages
English (en)
Inventor
David Berd
Laurence C Eisenlohr
Edmund Lattime
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Application granted granted Critical
Publication of ATE386535T1 publication Critical patent/ATE386535T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/18Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
AT96921381T 1995-06-07 1996-06-06 Hapten modifizierter tumorzellextrakt und verfahren zur behandlung von krebs ATE386535T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47901695A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ATE386535T1 true ATE386535T1 (de) 2008-03-15

Family

ID=23902311

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921381T ATE386535T1 (de) 1995-06-07 1996-06-06 Hapten modifizierter tumorzellextrakt und verfahren zur behandlung von krebs

Country Status (11)

Country Link
EP (1) EP0837687B1 (de)
JP (1) JPH11507633A (de)
KR (1) KR19990022592A (de)
AT (1) ATE386535T1 (de)
AU (1) AU727316B2 (de)
BR (1) BR9609026A (de)
CA (1) CA2222135A1 (de)
DE (1) DE69637440T2 (de)
ES (1) ES2302337T3 (de)
IL (1) IL122455A0 (de)
WO (1) WO1996040173A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014206A1 (en) * 1996-10-04 1998-04-09 Thomas Jefferson University T cells mediating an immune response and methods of use
WO2000009140A1 (en) 1997-07-24 2000-02-24 Thomas Jefferson University Composition and method of using tumor cells
AU2686999A (en) * 1998-02-17 1999-08-30 Thomas Jefferson University Hapten-modified tumor cell membranes, and methods of making and using hapten-modified tumor cell membranes
AR020067A1 (es) * 1998-04-09 2002-04-10 Univ Jefferson Uso y composicion para inducir una respuesta anti-tumoral contra una metastasis de melanoma
BR9910187A (pt) * 1998-05-04 2002-01-29 Univ Jefferson Processo e composição para induzir uma resposta anti-tumor em um paciente mamìfero sofrendo de um tumor
US6248585B1 (en) * 1998-11-19 2001-06-19 Thomas Jefferson University Compositions for preserving haptenized tumor cells for use in vaccines
WO2000031542A1 (en) * 1998-11-24 2000-06-02 Thomas Jefferson University Detection of t cell stimulating tumor antigens
WO2000038710A2 (en) * 1998-12-30 2000-07-06 Thomas Jefferson University Dual hapten modified tumor cells and tumor polypeptides and methods of treating cancer
WO2000057911A2 (en) * 1999-03-16 2000-10-05 Thomas Jefferson University Hapten-conjugated mammalian cells and methods of making and using thereof
US7297330B2 (en) * 2000-02-04 2007-11-20 Thomas Jefferson University Low dose haptenized tumor cell and tumor cell extract immunotherapy
US20040076646A1 (en) * 2001-07-18 2004-04-22 Caplan Michael J. Haptenizing cancer cell components
AU2003243485A1 (en) 2002-06-10 2003-12-22 Avax Technologies Inc. Cryopreservation of haptenized tumor cells
WO2006017174A2 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Antibodies against cancer produced using masked cancer cells as immunogen
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2019165195A1 (en) 2018-02-22 2019-08-29 Srivastava Satish Combination therapy for the treatment of cancer
BR112021005540A2 (pt) * 2018-09-24 2021-06-29 Biovaxys Llc vacinas autólogas bi-haptenizadas e seus usos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01500119A (ja) * 1986-05-07 1989-01-19 スローン‐ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ Gm2に対する抗体の産生を賦活又は増強させるためのワクチン
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
GB2218420B (en) * 1988-04-12 1992-07-15 British Bio Technology Synthetic gene encoding interleukin 4
CA2013966C (en) * 1989-04-05 2000-03-07 Peter Y. S. Fung Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins
US5290551A (en) * 1990-05-08 1994-03-01 Thomas Jefferson University Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten
WO1995015334A1 (en) * 1993-11-30 1995-06-08 California Pacific Medical Center Research Institute cDNA PROBE FOR BREAST CANCER DIAGNOSIS AND TREATMENT
US7297330B2 (en) * 2000-02-04 2007-11-20 Thomas Jefferson University Low dose haptenized tumor cell and tumor cell extract immunotherapy

Also Published As

Publication number Publication date
ES2302337T3 (es) 2008-07-01
KR19990022592A (ko) 1999-03-25
BR9609026A (pt) 1999-07-06
AU6262096A (en) 1996-12-30
JPH11507633A (ja) 1999-07-06
AU727316B2 (en) 2000-12-07
MX9709733A (es) 1998-10-31
EP0837687B1 (de) 2008-02-20
DE69637440T2 (de) 2009-03-05
EP0837687A4 (de) 2001-06-27
WO1996040173A1 (en) 1996-12-19
IL122455A0 (en) 1998-06-15
CA2222135A1 (en) 1996-12-19
EP0837687A1 (de) 1998-04-29
DE69637440D1 (de) 2008-04-03

Similar Documents

Publication Publication Date Title
DE69637440D1 (de) Hapten modifizierter tumorzellextrakt und verfahren zur behandlung von krebs
ATE334702T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
DE69230789D1 (de) Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
EP0957161A4 (de) Verfahren zur aktivierung von menschlichen, antigen-aktivierenden zellen, aktivierte menschliche, antigen-aktivierende zellen und anwendungen derselben
DE69132098D1 (de) Verfahren zur amplifikation von nukleinsäuren
ATE284959T1 (de) Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung
DE69223284D1 (de) Methoden zur Bestimmung von Krebsmetastasen mittels Nukleinsäuren-Amplifikation
ATE56868T1 (de) Verfahren zur darstellung von proanthocyanidina2, pharmazeutische zusammensetzungen und ihre therapeutische verwendung.
ATE330002T1 (de) Verfahren zur herstellung von membranvesikeln
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
FI900808A0 (fi) Humant mannos bindande protein.
DE3583564D1 (de) Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
DE60126495D1 (de) Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
NO308396B1 (no) FremgangsmÕte ved fremstilling av substanser av polypeptidnatur
ATE429517T1 (de) Vervielfältigung und nachweis von ebv barf1 zur diagnose von nasopharyngealen karzinom
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
EP0716614A4 (de) Behandlung von menschlichen tumoren durch genetische transformation von menschlichen tumorzellen
DE3684868D1 (de) Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
SG72665A1 (en) Method and composition for determining the immunological activity of bioactive substances
ATE180277T1 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
DE60135232D1 (de) Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
RU93001102A (ru) Способ получения иммуномодулятора миелопида
Weeks et al. Laminin reduces HSV-1 spread from cell to cell in human keratinocyte cultures
ATE533507T1 (de) Nukleinsäure und entsprechendes protein mit der bezeichnung 238p1b2, geeignet zur behandlung und zum nachweis von krebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties